Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1526-8209(11)70943-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System.
Cancer Med
January 2025
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA.
Introduction: Emerging evidence suggests potential cardiovascular toxicities from oral endocrine therapies (ETs); however, results are conflicting. This study comprehensively examined adverse reactions of ETs and investigated cardiovascular and metabolic safety signals within the FDA Adverse Event Reporting System (FAERS).
Methods: Reports in the FAERS through December 2023 were analyzed for documented reactions to tamoxifen, letrozole, anastrozole, and exemestane in female breast cancer patients.
The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting.
Front Oncol
December 2024
Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated a survival benefit in the second-line treatment of patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However, identifying prognostic biomarkers remains a challenge. Thus, we aimed to assess the prognostic value of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET-CT) performed before CDK4/6 inhibitors initiation.
View Article and Find Full Text PDFRibociclib-induced autoimmune-like hepatitis: a case report.
J Chemother
November 2024
Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkiye.
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer represents the most prevalent subtype of breast cancer. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, in combination with endocrine therapy (ET), have shown substantial benefits in improving progression-free survival and, for ribociclib, an overall survival advantage. Despite clinical benefits, ribociclib is associated with elevated liver enzymes and severe liver dysfunction.
View Article and Find Full Text PDFSelection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial.
JAMA Netw Open
November 2024
Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Article Synopsis
- In early-stage breast cancer (EBC) patients, there is a need for biomarkers to predict the risk of late recurrence and the benefit from extended endocrine therapy (EET), specifically using the MammaPrint 70-gene assay to identify low-risk tumors.
- The study analyzed postmenopausal women with hormone receptor-positive EBC from the IDEAL trial to see if the MammaPrint assay could help decide between 2.5 years and 5 years of treatment with letrozole.
- Results showed that patients with low-risk tumors had a significant benefit of 10.1% for distant recurrence with longer treatment, while no significant benefits were found for high-risk or ultralow risk patients regarding treatment duration
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.
Oncol Res Treat
November 2024
Medical Department, iOMEDICO, Freiburg, Germany.
Introduction: The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In addition, so far lacking evidence for efficacy and safety on the combination of PAL with anastrozole, exemestane (1L), or letrozole (later line) was investigated.
Methods: The prospective, multicenter, multicohort phase 2 trial INGE-B enrolled adult patients with locally advanced, inoperable, or metastatic HR+/HER2- breast cancer in Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!